Investing.com -- Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term financial outlook under new leadership. The firm set a new price target of $98 on BioMarin shares.
BioMarin posted fourth-quarter revenue of $747 million, exceeding the $712 million consensus estimate, and provided 2025 guidance with both revenue and earnings expectations above Street estimates.
Oppenheimer highlighted the continued global rollout of Voxzogo, which it believes has sizable untapped potential, and projected 2025 sales of $945 million.
The firm noted BioMarin’s focus on operational efficiency, cost reductions, and strategic R&D investments, as well as upcoming pipeline catalysts, including data readouts for BMN 351 and BMN 333 later this year.
Oppenheimer raised its revenue estimates through 2027 and expects BioMarin’s cost transformation program to yield full benefits by 2026.
Related Articles
Oppenheimer upgrades BioMarin on long term outlook
Amgen India opens with $200 million investment plan through 2025
National Grid sells $1.7 billion US renewables arm to Brookfield
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.